Trial Profile

A Single-arm, Open-label, Single-center Study to Evaluate the Safety and Tolerability of Intravenous GEN6050X Gene Therapy in Ambulatory Boys With Duchenne Muscular Dystrophy (DMD)

Status: Active, no longer recruiting

Phase of Trial: Phase 0

Latest Information Update: 18 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Jul 2025 Status changed from recruiting to active, no longer recruiting.
06 Mar 2025 According to a GenAssist Ltd media release, data from this study will be presented at 2025 Muscular Dystrophy Association (MDA) Conference,from March 16-19th, 2025 at Hilton Anatole, Dallas, TX.
06 Mar 2025 Results of topline efficacy data and Safety Update of GEN6050X for the First two Participants Dosed, published in the GenAssist Ltd Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com